论文部分内容阅读
目的系统评价阿奇霉素序贯治疗小儿支原体肺炎的临床有效性和安全性。方法采用计算机和手工检索相结合的方法,检索2005年1月—2012年9月国内公开发表的有关阿奇霉素序贯治疗小儿支原体肺炎的相关文献,采用RevMan5.0对符合条件的文献进行Meta分析。结果共有9篇文献,737例患者满足纳入标准。合并分析结果显示,临床有效率方面的比数比(OR)为3.87,95%可信区间(CI)为(2.23~6.71);不良反应发生率方面的OR为0.16,95%CI为(0.11~0.24)。结论阿奇霉素序贯治疗小儿支原体肺炎的临床有效率优于对照组,且不良反应少于对照组。
Objective To systematically evaluate the clinical efficacy and safety of azithromycin sequential therapy in children with mycoplasma pneumonia. Methods A computer-based manual search method was used to search the published literature about the sequential treatment of azithromycin in children with mycoplasma pneumonia from January 2005 to September 2012. Meta-analysis was performed on the eligible literature using RevMan 5.0. Results A total of 9 articles were included and 737 patients met the inclusion criteria. The pooled analysis showed that the odds ratio (OR) for clinical efficiency was 3.87, the 95% confidence interval (CI) was (2.23 to 6.71), the OR for adverse events was 0.16, and the 95% CI was 0.11 ~ 0.24). Conclusion The sequential treatment of azithromycin in children with mycoplasma pneumonia clinical efficacy is better than the control group, and adverse reactions less than the control group.